



(51) International Patent Classification:

C07D 239/54 (2006.01) A61K 45/06 (2006.01)
C07F 9/6512 (2006.01) A61K 31/675 (2006.01)
A61K 31/513 (2006.01)

(21) International Application Number:

PCT/US2013/026062

(22) International Filing Date:

14 February 2013 (14.02.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/598,524 14 February 2012 (14.02.2012) US
61/615,989 27 March 2012 (27.03.2012) US
61/615,975 27 March 2012 (27.03.2012) US

(71) Applicant: UNIVERSITY OF GEORGIA RESEARCH
FOUNDATION, INC. [US/US]; 6th Floor, Boyd Gradu-
ate Studies, Research Building, 200 D.W. Brooks Drive,
Athens, GA 30602-7411 (US).

(72) Inventor: CHU, Chung, K.; 662 Garden Circle, Statham,
GA 30666 (US).

(74) Agent: BELLOWS, Brent, R.; Knowles Intellectual Prop-
erty Strategies, LLC, 400 Perimeter Center Terrace Ne,
Suite 125, Atlanta, GA 30346 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA,
ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

[Continued on next page]

(54) Title: SPIRO [2.4]HEPTANES FOR TREATMENT OF FLAVIVIRIDAE INFECTIONS

Synthesis of spiro[2.4]heptanes




FIG. 2

(57) Abstract: Compounds, methods, and compositions for
the treatment of infections in or exposure to humans and
other host animals of Flaviviridae viruses, including HCV,
that includes the administration of an effective amount of a
spiro[2.4]heptane as described herein or a pharmaceutically
acceptable salt or prodrug thereof, optionally in a pharma-
ceutically acceptable carrier, are provided. The
spiro[2.4]heptane compounds either possess antiviral activ-
ity, or are metabolized to a compound that exhibits such
activity.



TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, **Published:**
ML, MR, NE, SN, TD, TG).

— *without international search report and to be republished
upon receipt of that report (Rule 48.2(g))*